These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 15276394)

  • 1. Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial.
    Anand I; McMurray J; Cohn JN; Konstam MA; Notter T; Quitzau K; Ruschitzka F; Lüscher TF;
    Lancet; 2004 Jul 24-30; 364(9431):347-54. PubMed ID: 15276394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurohumoral and hemodynamic effects of the selective endothelin antagonist darusentan in advanced chronic heart failure.
    Bergler-Klein J; Pacher R; Berger R; Bojic A; Stanek B
    J Heart Lung Transplant; 2004 Jan; 23(1):20-7. PubMed ID: 14734123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial.
    Weber MA; Black H; Bakris G; Krum H; Linas S; Weiss R; Linseman JV; Wiens BL; Warren MS; Lindholm LH
    Lancet; 2009 Oct; 374(9699):1423-31. PubMed ID: 19748665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT).
    Lüscher TF; Enseleit F; Pacher R; Mitrovic V; Schulze MR; Willenbrock R; Dietz R; Rousson V; Hürlimann D; Philipp S; Notter T; Noll G; Ruschitzka F;
    Circulation; 2002 Nov; 106(21):2666-72. PubMed ID: 12438291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective ETA receptor blockade prevents left ventricular remodeling and deterioration of cardiac function in experimental heart failure.
    Mulder P; Richard V; Bouchart F; Derumeaux G; Münter K; Thuillez C
    Cardiovasc Res; 1998 Sep; 39(3):600-8. PubMed ID: 9861302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beneficial effects of long-term selective endothelin type A receptor blockade in canine experimental heart failure.
    Moe GW; Albernaz A; Naik GO; Kirchengast M; Stewart DJ
    Cardiovasc Res; 1998 Sep; 39(3):571-9. PubMed ID: 9861299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment with darusentan over 21 days improved cGMP generation in patients with chronic heart failure.
    Philipp S; Monti J; Pagel I; Langenickel T; Notter T; Ruschitzka F; Lüscher T; Dietz R; Willenbrock R
    Clin Sci (Lond); 2002 Aug; 103 Suppl 48():249S-253S. PubMed ID: 12193097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of darusentan: a novel endothelin receptor antagonist.
    Epstein BJ
    Ann Pharmacother; 2008 Jul; 42(7):1060-9. PubMed ID: 18523233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual Endothelin-A/Endothelin-B Receptor Blockade and Cardiac Remodeling in Heart Failure With Preserved Ejection Fraction.
    Valero-Munoz M; Li S; Wilson RM; Boldbaatar B; Iglarz M; Sam F
    Circ Heart Fail; 2016 Nov; 9(11):. PubMed ID: 27810862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endothelin receptor antagonists in heart failure: current status and future directions.
    Ertl G; Bauersachs J
    Drugs; 2004; 64(10):1029-40. PubMed ID: 15139784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in ventricular remodelling and clinical status during the year following a single administration of stromal cell-derived factor-1 non-viral gene therapy in chronic ischaemic heart failure patients: the STOP-HF randomized Phase II trial.
    Chung ES; Miller L; Patel AN; Anderson RD; Mendelsohn FO; Traverse J; Silver KH; Shin J; Ewald G; Farr MJ; Anwaruddin S; Plat F; Fisher SJ; AuWerter AT; Pastore JM; Aras R; Penn MS
    Eur Heart J; 2015 Sep; 36(33):2228-38. PubMed ID: 26056125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of endothelin ETA receptor blocker LU 135252 on cardiac remodeling and survival in a hypertensive rat model of chronic heart failure.
    Xia QG; Reinecke A; Dorenkamp M; Daemen MJ; Simon R; Unger T
    Acta Pharmacol Sin; 2006 Nov; 27(11):1417-22. PubMed ID: 17049116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of systemic endothelin A receptor antagonism in various vascular beds in men: in vivo interactions of the major blood pressure-regulating systems and associations with the GNB3 C825T polymorphism.
    Mitchell A; Lückebergfeld B; Bührmann S; Rushentsova U; Nürnberger J; Siffert W; Schäfers RF; Philipp T; Wenzel RR
    Clin Pharmacol Ther; 2004 Nov; 76(5):396-408. PubMed ID: 15536455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Darusentan: an effective endothelinA receptor antagonist for treatment of hypertension.
    Nakov R; Pfarr E; Eberle S;
    Am J Hypertens; 2002 Jul; 15(7 Pt 1):583-9. PubMed ID: 12118903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baseline characteristics of patients recruited in the AREA IN-CHF study (Antiremodelling Effect of Aldosterone Receptors Blockade with Canrenone in Mild Chronic Heart Failure).
    Boccanelli A; Cacciatore G; Mureddu GF; de Simone G; Clemenza F; De Maria R; Di Lenarda A; Gavazzi A; Latini R; Masson S; Porcu M; Vanasia M; Gonzini L; Maggioni AP
    J Cardiovasc Med (Hagerstown); 2007 Sep; 8(9):683-91. PubMed ID: 17700397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction.
    Udelson JE; McGrew FA; Flores E; Ibrahim H; Katz S; Koshkarian G; O'Brien T; Kronenberg MW; Zimmer C; Orlandi C; Konstam MA
    J Am Coll Cardiol; 2007 Jun; 49(22):2151-9. PubMed ID: 17543634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study.
    Black HR; Bakris GL; Weber MA; Weiss R; Shahawy ME; Marple R; Tannoury G; Linas S; Wiens BL; Linseman JV; Roden R; Gerber MJ
    J Clin Hypertens (Greenwich); 2007 Oct; 9(10):760-9. PubMed ID: 17917503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of losartan and captopril on left ventricular volumes in elderly patients with heart failure: results of the ELITE ventricular function substudy.
    Konstam MA; Patten RD; Thomas I; Ramahi T; La Bresh K; Goldman S; Lewis W; Gradman A; Self KS; Bittner V; Rand W; Kinan D; Smith JJ; Ford T; Segal R; Udelson JE
    Am Heart J; 2000 Jun; 139(6):1081-7. PubMed ID: 10827391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial.
    Bakris GL; Lindholm LH; Black HR; Krum H; Linas S; Linseman JV; Arterburn S; Sager P; Weber M
    Hypertension; 2010 Nov; 56(5):824-30. PubMed ID: 20921430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction. The carvedilol and ACE-inhibitor remodelling mild heart failure evaluation trial (CARMEN).
    Remme WJ; Riegger G; Hildebrandt P; Komajda M; Jaarsma W; Bobbio M; Soler-Soler J; Scherhag A; Lutiger B; Rydén L
    Cardiovasc Drugs Ther; 2004 Jan; 18(1):57-66. PubMed ID: 15115904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.